Q-omics provides the consensus-scored CFDP1 profile across patient tissues and cancer cell-line models. CFDP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CFDP1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CFDP1 RNA expression shows 19,063 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRC, and ACC as cancer lineages where CFDP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFDP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFDP1 survival associations across molecular data types. CFDP1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFDP1 RNA expression–survival associations across cancer types. High CFDP1 expression shows unfavorable associations in HNSC, BRCA, STAD, LIHC and BLCA, but favorable associations in LGG. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CFDP1 RNA expression.
This table summarizes CFDP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CFDP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFDP1 shows lower tumor expression in KICH, UCEC and THCA and higher tumor expression in KIRC, HNSC and LIHC. The KIRC box plot shows higher CFDP1 RNA expression in tumor versus normal tissue (log2 FC = +0.744, t-test p < 0.001).
This table shows molecular features associated with CFDP1 in patient tissues and cancer cell lines. In patient samples, CFDP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CFDP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
